company background image
AZTA

Azenta NasdaqGS:AZTA Stock Report

Last Price

US$74.29

Market Cap

US$5.5b

7D

8.2%

1Y

-21.2%

Updated

26 Jun, 2022

Data

Company Financials +
AZTA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AZTA Stock Overview

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally.

Azenta Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Azenta
Historical stock prices
Current Share PriceUS$74.29
52 Week HighUS$124.79
52 Week LowUS$61.35
Beta1.66
1 Month Change1.38%
3 Month Change-12.91%
1 Year Change-21.19%
3 Year Change91.72%
5 Year Change242.51%
Change since IPO642.90%

Recent News & Updates

Shareholder Returns

AZTAUS Life SciencesUS Market
7D8.2%8.4%6.6%
1Y-21.2%-15.9%-18.4%

Return vs Industry: AZTA underperformed the US Life Sciences industry which returned -15.9% over the past year.

Return vs Market: AZTA underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is AZTA's price volatile compared to industry and market?
AZTA volatility
AZTA Average Weekly Movement7.3%
Life Sciences Industry Average Movement11.4%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: AZTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: AZTA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19782,900Steve Schwartzhttps://www.azenta.com

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows.

Azenta Fundamentals Summary

How do Azenta's earnings and revenue compare to its market cap?
AZTA fundamental statistics
Market CapUS$5.53b
Earnings (TTM)-US$23.20m
Revenue (TTM)US$551.22m

10.0x

P/S Ratio

-238.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AZTA income statement (TTM)
RevenueUS$551.22m
Cost of RevenueUS$284.78m
Gross ProfitUS$266.44m
Other ExpensesUS$289.64m
Earnings-US$23.20m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.31
Gross Margin48.34%
Net Profit Margin-4.21%
Debt/Equity Ratio0%

How did AZTA perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

-64%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is AZTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AZTA?

Other financial metrics that can be useful for relative valuation.

AZTA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.7x
Enterprise Value/EBITDA38.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AZTA's PS Ratio compare to its peers?

AZTA PS Ratio vs Peers
The above table shows the PS ratio for AZTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.1x

Price-To-Sales vs Peers: AZTA is expensive based on its Price-To-Sales Ratio (10x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does AZTA's PE Ratio compare vs other companies in the U.S. Life Sciences Industry?

Price-To-Sales vs Industry: AZTA is expensive based on its Price-To-Sales Ratio (10x) compared to the US Life Sciences industry average (5.2x)


Price to Sales Ratio vs Fair Ratio

What is AZTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AZTA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10x
Fair PS Ratio5.4x

Price-To-Sales vs Fair Ratio: AZTA is expensive based on its Price-To-Sales Ratio (10x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).


Share Price vs Fair Value

What is the Fair Price of AZTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AZTA ($74.29) is trading below our estimate of fair value ($108.06)

Significantly Below Fair Value: AZTA is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AZTA's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Azenta forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-103.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZTA's earnings are forecast to decline over the next 3 years (-103.2% per year).

Earnings vs Market: AZTA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AZTA is expected to become profitable in the next 3 years.

Revenue vs Market: AZTA's revenue (20.1% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: AZTA's revenue (20.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AZTA's Return on Equity is forecast to be low in 3 years time (2.2%).


Discover growth companies

Past Performance

How has Azenta performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-50.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AZTA is currently unprofitable.

Growing Profit Margin: AZTA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AZTA is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.

Accelerating Growth: Unable to compare AZTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AZTA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (21%).


Return on Equity

High ROE: AZTA has a negative Return on Equity (-0.67%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Azenta's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AZTA's short term assets ($3.0B) exceed its short term liabilities ($618.0M).

Long Term Liabilities: AZTA's short term assets ($3.0B) exceed its long term liabilities ($76.1M).


Debt to Equity History and Analysis

Debt Level: AZTA is debt free.

Reducing Debt: AZTA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AZTA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AZTA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Azenta current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.54%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: AZTA's dividend (0.54%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.57%).

High Dividend: AZTA's dividend (0.54%) is low compared to the top 25% of dividend payers in the US market (4.24%).


Stability and Growth of Payments

Stable Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: AZTA is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: AZTA is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: AZTA is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average management tenure


CEO

Steve Schwartz (62 yo)

11.67yrs

Tenure

US$5,290,656

Compensation

Dr. Stephen S. Schwartz, also known as Steve, is a Director Azenta US, Inc. He is President and Chief Executive Officer at Azenta US, Inc. He has been Chief Executive Officer of Azenta, Inc. (formerly know...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD5.29M) is below average for companies of similar size in the US market ($USD8.44M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AZTA's management team is seasoned and experienced (7.9 years average tenure).


Board Members

Experienced Board: AZTA's board of directors are seasoned and experienced ( 11 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AZTA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Azenta, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Azenta, Inc.
  • Ticker: AZTA
  • Exchange: NasdaqGS
  • Founded: 1978
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.530b
  • Shares outstanding: 74.43m
  • Website: https://www.azenta.com

Number of Employees


Location

  • Azenta, Inc.
  • 15 Elizabeth Drive
  • Chelmsford
  • Massachusetts
  • 1824
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.